Conduit Pharmaceuticals (CDT) Competitors $0.10 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends CDT vs. BRNS, ANEB, CVM, LUMO, OSTX, CERO, OKYO, RAPT, ELEV, and NXTCShould you be buying Conduit Pharmaceuticals stock or one of its competitors? The main competitors of Conduit Pharmaceuticals include Barinthus Biotherapeutics (BRNS), Anebulo Pharmaceuticals (ANEB), CEL-SCI (CVM), Lumos Pharma (LUMO), OS Therapies (OSTX), CERo Therapeutics (CERO), OKYO Pharma (OKYO), RAPT Therapeutics (RAPT), Elevation Oncology (ELEV), and NextCure (NXTC). These companies are all part of the "pharmaceutical products" industry. Conduit Pharmaceuticals vs. Barinthus Biotherapeutics Anebulo Pharmaceuticals CEL-SCI Lumos Pharma OS Therapies CERo Therapeutics OKYO Pharma RAPT Therapeutics Elevation Oncology NextCure Conduit Pharmaceuticals (NASDAQ:CDT) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Does the media prefer CDT or BRNS? In the previous week, Conduit Pharmaceuticals and Conduit Pharmaceuticals both had 5 articles in the media. Conduit Pharmaceuticals' average media sentiment score of 0.42 beat Barinthus Biotherapeutics' score of 0.00 indicating that Conduit Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Conduit Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Barinthus Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend CDT or BRNS? Barinthus Biotherapeutics has a consensus target price of $5.83, indicating a potential upside of 551.99%. Given Barinthus Biotherapeutics' higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Conduit Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Conduit Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor CDT or BRNS? Barinthus Biotherapeutics received 13 more outperform votes than Conduit Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformConduit PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesBarinthus BiotherapeuticsOutperform Votes14100.00% Underperform VotesNo Votes Which has stronger valuation & earnings, CDT or BRNS? Conduit Pharmaceuticals has higher earnings, but lower revenue than Barinthus Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConduit PharmaceuticalsN/AN/A-$540KN/AN/ABarinthus Biotherapeutics$800K44.22-$73.35M-$1.49-0.60 Is CDT or BRNS more profitable? Conduit Pharmaceuticals' return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Conduit PharmaceuticalsN/A N/A -320.58% Barinthus Biotherapeutics N/A -34.26%-29.30% Which has more volatility and risk, CDT or BRNS? Conduit Pharmaceuticals has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.59, suggesting that its stock price is 159% less volatile than the S&P 500. Do insiders and institutionals hold more shares of CDT or BRNS? 3.3% of Conduit Pharmaceuticals shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 34.7% of Conduit Pharmaceuticals shares are held by company insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryConduit Pharmaceuticals beats Barinthus Biotherapeutics on 7 of the 13 factors compared between the two stocks. Ad Genesis Gold GroupBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDT vs. The Competition Export to ExcelMetricConduit PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.98M$7.01B$5.38B$8.84BDividend YieldN/A8.11%5.11%4.09%P/E RatioN/A11.01105.9717.81Price / SalesN/A389.861,247.60162.50Price / CashN/A52.5940.2336.29Price / Book-1.1610.377.076.50Net Income-$540,000.00$153.60M$119.40M$226.10M7 Day PerformanceN/A4.53%2.16%3.98%1 Month Performance-8.13%-7.75%-3.12%3.79%1 Year Performance-93.92%33.34%33.73%29.31% Conduit Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTConduit PharmaceuticalsN/A$0.10flatN/A-93.9%$9.98MN/A0.003News CoverageHigh Trading VolumeBRNSBarinthus Biotherapeutics1.6517 of 5 stars$0.99+10.0%$5.83+490.3%-69.8%$39.08M$800,000.00-0.60107Analyst ForecastGap UpANEBAnebulo Pharmaceuticals2.5286 of 5 stars$1.50-1.3%$8.00+433.3%-30.8%$38.90MN/A-5.004Analyst ForecastNews CoverageHigh Trading VolumeCVMCEL-SCIN/A$0.60-3.2%N/A-74.6%$38.57MN/A-1.0443Analyst DowngradeNews CoverageLUMOLumos Pharma2.621 of 5 stars$4.33+0.2%$8.63+99.2%+39.9%$37.45M$2.05M-1.0130High Trading VolumeOSTXOS TherapiesN/A$1.86+7.5%N/AN/A$36.64MN/A0.00N/ACEROCERo TherapeuticsN/A$0.24-4.0%N/AN/A$36.47MN/A0.008Gap DownOKYOOKYO Pharma2.1584 of 5 stars$1.07flat$7.00+554.2%-38.2%$36.21MN/A0.007RAPTRAPT Therapeutics4.5415 of 5 stars$1.04-3.7%$9.50+817.9%-92.1%$36.18M$1.53M-0.3780ELEVElevation Oncology2.3778 of 5 stars$0.61+5.2%$7.80+1,174.9%+30.7%$36.17MN/A-0.7540News CoverageNXTCNextCure4.4032 of 5 stars$1.29-0.8%$4.00+210.1%-4.8%$36.13MN/A-0.6290 Related Companies and Tools Related Companies Barinthus Biotherapeutics Alternatives Anebulo Pharmaceuticals Alternatives CEL-SCI Alternatives Lumos Pharma Alternatives OS Therapies Alternatives CERo Therapeutics Alternatives OKYO Pharma Alternatives RAPT Therapeutics Alternatives Elevation Oncology Alternatives NextCure Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CDT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDT Stock Alerts